Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 15;10:54. doi: 10.3389/fphar.2019.00054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Nežić, Amidžić, Škrbić, Gajanin, Nepovimova, Vališ, Kuča and Jaćević.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Simvastatin increased survivin expression in rat liver in LPS-induced inflammation. Distribution of survivin-positive hepatocytes that were challenged with a non-lethal dose of LPS or either pretreated with simvastatin 40 mg/kg before LPS, magnification 400x. (A) Control group. (B) Note significant increase in the number of survivin-positive hepatocytes with intensive cytoplasmic staining in the LPS group, (C) Simvastatin 40 mg/kg + LPS group. Simvastatin increased survivin expression in rat spleen in LPS-induced inflammation. Distribution of survivin-positive lymphocytes that were challenged with a non-lethal dose of LPS or either pretreated with simvastatin 40 mg/kg before LPS, magnification 400×. (D) Control group. (E) Note significant increase in a number of survivin-positive lymphocytes with intensive cytoplasmic staining in the LPS group, and (F) Simvastatin 40 mg/kg + LPS group.